Recently the combination of PD-1 inhibition and platinum-based chemotherapy has shown a superior OS in patients with Her-2 negative adenocarcinoma and a PD-L1 combined prognostic score (CPS) of more than 5 or 10 respectively (Janjigian et al. 2021; Sun et al. 2021). The gene discussed is CD274; the disease is adenocarcinoma.